Y42 Funds

In August 2020, NewRelic (NEWR) did a huge clean-up on its pricing. The previous was primarily a contract determined by the number of hosts and their runtime ( example , but thankfully they didn't equate containers as hosts), and bundled with a support package.  New pricing no longer looks at hosts but # of users and GB of ingestion, which make up its subscription + usage (also referred to as "Pay as You Go"). Designated support package is only available for the highest tier. NewRelic however doesn't (or hasn't yet started to) report these 3 revenue sources (subscription, Pay as You Go, support) separately. The following sums up my understanding of its implications: Stopping the churn. Retaining as many users as possible on its free tier, as they lose appetite immediately when there's a commitment. Atlassian (TEAM) is now using a similar strategy -- "free for small teams". Incurring short-term drop in ARR, as they expected too. Also makes it a slight

At the end of Q1, 3% out of the whole Y42 Funds is comprised of Malaysian equities (traded through Bursa Malaysia, MYX). The S11 Fund (stands for Consumer S taples), which makes up 29.6% of Y42, has been rebalancing out its remaining MYX portfolio over the last 1 year, substituted by better performing ETFs and stocks primarily listed on HKEx and SGX. The rebalancing is largely logical given MYX has underperformed the broader market in the last 5 years. However, the stock picks have more to be blamed for the overall performance (-11.6%, with currency effect included).  With these pandemic-accelerated exits, the H11 Fund maintains at a CAGR of 18.9% (since 2010) and S11 Fund at 1.56% (since 2016). 

We have seen weakness in almost every sector in the market since the pandemic. On Friday, Thai Beverage, owned by Thailand largest conglomerate TCC Group, reported -7.4% drop in revenue (YoY, worsened from  -3.9%  reported a quarter ago), which was made less severe by improvement in May, especially in its Spirits and NAB segments.  The mid-term strategy for these beverage makers is to innovate on D2C and B2B2Home , and to optimize its marketing spending on their stronger brands towards off-premise consumers, and perhaps anchoring in the long term if they pay off. While the adaptation is innovative, it however doesn't make us (in terms of health and economy) less susceptible to future pandemic diseases. My thesis for a more prosperous society, therefore, is to invest in technology that advances the diagnosis, treatment, and the R&D of vaccines (not the development of vaccine against Covid-19 alone).  (Source: Healthcare Digital, 2020 ) My next step from here is to navigate and

I'm a technologist who loves discovering and investing in great companies. I am still trying to figure out the best way to share my portfolio openly, it is currently below $1M.  This blog focuses on my hypotheses and decision-making process. I'll come back to update this entry to tell more stories about myself.